BIOMAT Database Logo BIOMAT Database Logo

Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. 1999

V B Oza, and H M Petrassi, and H E Purkey, and J W Kelly
Department of Chemistry, Scripps Research Institute, La Jolla, CA 92037, USA.

Eight small molecules were synthesized to evaluate the structure activity relationships (SAR) of N-substituted anthranilic acids. The molecules were synthesized by benzylation or arylation of methyl anthranilate. A light scattering-based amyloid fibril formation assay was used to evaluate potential inhibitors of transthyretin (TTR) amyloid fibril formation in vitro. The m-carboxyphenylated and o-trifluoromethylphenylated anthranilic acids are potent inhibitors that will be subjected to further SAR and structural analysis.

UI MeSH Term Description Entries
D008027 Light That portion of the electromagnetic spectrum in the visible, ultraviolet, and infrared range. Light, Visible,Photoradiation,Radiation, Visible,Visible Radiation,Photoradiations,Radiations, Visible,Visible Light,Visible Radiations
D011228 Prealbumin A tetrameric protein, molecular weight between 50,000 and 70,000, consisting of 4 equal chains, and migrating on electrophoresis in 3 fractions more mobile than serum albumin. Its concentration ranges from 7 to 33 per cent in the serum, but levels decrease in liver disease. Proalbumin,Transthyretin
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005439 Flufenamic Acid An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16) Dignodolin,Acid, Flufenamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000682 Amyloid A fibrous protein complex that consists of proteins folded into a specific cross beta-pleated sheet structure. This fibrillar structure has been found as an alternative folding pattern for a variety of functional proteins. Deposits of amyloid in the form of AMYLOID PLAQUES are associated with a variety of degenerative diseases. The amyloid structure has also been found in a number of functional proteins that are unrelated to disease. Amyloid Fibril,Amyloid Fibrils,Amyloid Substance,Fibril, Amyloid,Fibrils, Amyloid,Substance, Amyloid
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D012542 Scattering, Radiation The diversion of RADIATION (thermal, electromagnetic, or nuclear) from its original path as a result of interactions or collisions with atoms, molecules, or larger particles in the atmosphere or other media. (McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Radiation Scattering,Radiation Scatterings,Scatterings, Radiation
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

V B Oza, and H M Petrassi, and H E Purkey, and J W Kelly
Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action.
June 2003, Angewandte Chemie (International ed. in English),
V B Oza, and H M Petrassi, and H E Purkey, and J W Kelly
Synthesis of 4H-1,4-oxazines as transthyretin amyloid fibril inhibitors.
July 2013, Organic & biomolecular chemistry,
V B Oza, and H M Petrassi, and H E Purkey, and J W Kelly
Novel transthyretin amyloid fibril formation inhibitors: synthesis, biological evaluation, and X-ray structural analysis.
July 2009, PloS one,
V B Oza, and H M Petrassi, and H E Purkey, and J W Kelly
Anthranilic acid-based inhibitors of phosphodiesterase: design, synthesis, and bioactive evaluation.
October 2011, Organic & biomolecular chemistry,
V B Oza, and H M Petrassi, and H E Purkey, and J W Kelly
Discovering transthyretin amyloid fibril inhibitors by limited screening.
August 1998, Bioorganic & medicinal chemistry,
V B Oza, and H M Petrassi, and H E Purkey, and J W Kelly
Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation.
March 2005, Journal of medicinal chemistry,
V B Oza, and H M Petrassi, and H E Purkey, and J W Kelly
Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid.
July 1999, Bioorganic & medicinal chemistry,
V B Oza, and H M Petrassi, and H E Purkey, and J W Kelly
Monoaryl derivatives as transthyretin fibril formation inhibitors: Design, synthesis, biological evaluation and structural analysis.
September 2020, Bioorganic & medicinal chemistry,
V B Oza, and H M Petrassi, and H E Purkey, and J W Kelly
Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma.
May 2001, Proceedings of the National Academy of Sciences of the United States of America,
V B Oza, and H M Petrassi, and H E Purkey, and J W Kelly
Oxidation inhibits amyloid fibril formation of transthyretin.
December 2006, The FEBS journal,
Copied contents to your clipboard!